Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 35

Results For "Head"

1959 News Found

Argo Biopharma inks $5.2 billion deal with Novartis for novel molecules for cardiovascular diseases
News | September 08, 2025

Argo Biopharma inks $5.2 billion deal with Novartis for novel molecules for cardiovascular diseases

Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity


HealthEdge and UST HealthProof Merge to create AI-powered healthcare payer technology
Digitisation | September 08, 2025

HealthEdge and UST HealthProof Merge to create AI-powered healthcare payer technology

Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans


Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC
Clinical Trials | September 06, 2025

Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC

The company has received approval from DCGI to begin patient enrolment and dosing in the country


CapVest to acquire majority stake in STADA
News | September 05, 2025

CapVest to acquire majority stake in STADA

Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth


Quotient Sciences and CPI join forces to accelerate RNA drug development
News | September 05, 2025

Quotient Sciences and CPI join forces to accelerate RNA drug development

The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products


Syntegon reports H1 2025 EBITDA higher by 41% to €127 million
News | September 04, 2025

Syntegon reports H1 2025 EBITDA higher by 41% to €127 million

Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024


Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain
News | September 03, 2025

Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain

The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes


FDA approves Sanofi’s BTK inhibitor for immune thrombocytopenia
Drug Approval | September 02, 2025

FDA approves Sanofi’s BTK inhibitor for immune thrombocytopenia

ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life


Glenmark Pharmaceuticals USA to launch Eribulin Mesylate injection
News | September 02, 2025

Glenmark Pharmaceuticals USA to launch Eribulin Mesylate injection

Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai